Feature interview with Founder Mustafa Can highlights Carmed’s research-driven philosophy as products launch on OneLavi.com and prepare for Amazon rollFeature interview with Founder Mustafa Can highlights Carmed’s research-driven philosophy as products launch on OneLavi.com and prepare for Amazon roll

Carmed Pharmaceuticals Highlights CityBiz Feature as U.S. Expansion Accelerates

2026/05/22 17:00
4분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다
Boca Raton, Florida (Newsworthy.ai) Friday May 22, 2026 @ 5:00 AM Eastern —

Carmed Pharmaceuticals, a Turkey-based, science-driven company specializing in standardized carvacrol-based formulations, has earned editorial coverage in CityBiz through a featured executive Q&A with Founder Mustafa Can as the company continues expanding into the United States market.

The CityBiz interview explores Can’s unconventional journey from ship master in the maritime industry to founder of a research-focused pharmaceutical company built around standardized botanical formulations and long-term scientific development. The feature also discusses Carmed’s formulation philosophy, ongoing research initiatives, and strategy for entering the U.S. wellness market.

Founder Story and Research-Driven Philosophy

In the interview, Can explains how a personal interest in longevity and preventive wellness led him into years of independent research studying botanical compounds and formulation science before formally establishing Carmed Pharmaceuticals.

“Over time, this personal journey evolved into something more structured,” Can said in the CityBiz feature. “I became increasingly focused on how to develop standardized, reproducible formulations based on bioactive compounds like carvacrol.”

The article also highlights Carmed’s emphasis on what the company describes as “rational synergy” – combining multiple bioactive compounds within standardized formulations designed around consistency, reproducibility, and analytical validation.

Building Awareness Ahead of Broader U.S. Distribution

The CityBiz placement comes as Carmed continues building awareness in the United States through a multi-channel distribution strategy that includes both curated wellness platforms and large-scale digital marketplaces.

Several Carmed formulations are now available on OneLavi.com, including:

  • Vacrol® Kids Spray – A carvacrol-based spray formulated to support upper respiratory wellness and microbial balance for children ages 4-11.

  • S-Mix® – A synergy-driven formulation designed to support immune function and healthy cellular activity.

  • Vacrol® Capsule – A standardized carvacrol formulation developed to support microbial balance and immune resilience.

  • Vacrol-M® Capsule – A multi-component botanical formulation designed to support immune function and respiratory wellness.

Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified.

The company also previously announced plans to expand availability through Amazon as part of its broader U.S. rollout strategy.

Scientific Collaboration and Ongoing Research

The CityBiz interview also discusses Carmed’s commitment to scientific collaboration and ongoing research. According to the feature, Carmed works alongside physicians, researchers, laboratories, and academic partners to support formulation development and scientific evaluation.

In January 2026, research involving Carmed formulations Vacrol® and S-Mix® was published in the peer-reviewed journal Plants, where the formulations were examined in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based botanical formulations.

The company emphasizes that this research reflects scientific investigation into formulation science and botanical bioactivity and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.

Expanding a Long-Term U.S. Presence

Carmed states that its U.S. strategy is focused on long-term brand development through scientific credibility, regulatory alignment, educational visibility, and expanded consumer accessibility.

“Our goal is to build a company that is known for consistency, credibility, and a long-term commitment to research-driven development,” Can said in the CityBiz feature.

The full CityBiz Q&A with Mustafa Can can be viewed here.

About Carmed Pharmaceuticals

Carmed Pharmaceuticals is a research-driven company specializing in standardized, mechanism-based botanical formulations rooted in Anatolia’s rich botanical heritage. Integrating traditional plant knowledge with modern pharmaceutical technology, Carmed focuses on analytical validation, quality control, and reproducible formulation design.

Officially established in 2019 following years of focused research and development, the company operates with nearly 15 years of industry experience. All products are manufactured in accordance with Good Manufacturing Practice (GMP) principles and relevant regulatory standards, emphasizing safe production, environmental awareness, and continuous quality improvement.

Carmed develops standardized formulations designed to support preventive wellness, immune resilience, and cellular health through science-informed, quality-controlled processes.

Visit Carmed Pharmaceuticals website and visit them on Instagram.


This press release is distributed by the Newsworthy.ai™ Press Release Newswire – News Marketing Platform™. The reference URL for this press release is located here Carmed Pharmaceuticals Highlights CityBiz Feature as U.S. Expansion Accelerates.

The post Carmed Pharmaceuticals Highlights CityBiz Feature as U.S. Expansion Accelerates appeared first on citybuzz.

시장 기회
United Stables 로고
United Stables 가격(U)
$1.001
$1.001$1.001
0.00%
USD
United Stables (U) 실시간 가격 차트

SPACEX(PRE) Launchpad Is Live

SPACEX(PRE) Launchpad Is LiveSPACEX(PRE) Launchpad Is Live

Start with $100 to share 6,000 SPACEX(PRE)

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

No Chart Skills? Still Profit

No Chart Skills? Still ProfitNo Chart Skills? Still Profit

Copy top traders in 3s with auto trading!